The European Melanoma Registry

“While the total number of cancer incidences is dropping, the number of cases of melanoma is increasing at a rate of 3-7% in many European countries. We need to analyse more data in order to improve diagnosis and develop novel therapies.”

Lidija Kandolf Sekulovic, Serbia

“A rapidly accumulating and massive high-quality real-life data can be obtained only when hands are joined. The conclusions we get from analysing such data allow us to better understand skin cancers and treatment effects. It allows us to formulate burning and important clinical questions and receive the results promptly, in real-time. This is a huge advantage that takes us one step further toward curing cancer. I'm proud to take part in this international collaborative project!”

Nethanel Asher, Israel

“Our advances and success in melanoma research are the result of a true team effort including international collaborations. World class cancer registries are highly needed for patient stratification strategies, as well as in order to translate the results of clinical trials in unselected patient populations and monitor patient care.”

Johanna Mangana, Switzerland

“Real-world data is crucial to validate clinical trial data. Generally, patients enrolled in clinical trials are selected in comparison to patients treated in real life (who are often in worse condition). Analysing data from a large number of real-life patients allows us to assess the true impact of new therapies in clinical practice. This is why a clinical registry such as the European Melanoma Registry is essential.”

Paolo Ascierto, Italy